Digital healthcare company NuvoAir has raised $11m funding as an extension of the Series A round, announced in June last year, to expand the patient-centric care and clinical trials platform.

This brings the total funding raised by the company in Series A round to $25m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The funding was led by Hikma Ventures, a venture capital arm of Hikma Pharmaceuticals, with participation from new strategic investors and existing investors.

NuvoAir will utilise the funds to expand its team and clinical trials platform, and speed up its clinical services launch with risk-bearing providers and Health Plans.

The company also plans to launch new clinical trial partnerships worldwide.

NuvoAir founder and CEO Lorenzo Consoli said: “We are really excited to have Hikma Ventures join our existing investors to help us expand our unique service model and technology to support a truly patient focused approach to delivering clinical care and clinical trials.”

The company is focused on treating complex patients, with an initial focus on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).

As a part of the chronic care ecosystem, NuvoAir launched Aos sensor as an add-on sensor for asthma and COPD inhalers in December last year.

The Aos sensor provides additional data that allows NuvoAir Care Coordinators and healthcare providers to evaluate inhaler technique, monitor inhaler use and assess effectiveness of the treatment.

NuvoAir Board chairman Gary Kurtzman said: “Healthcare is far too confusing and fragmented to navigate, particularly for complex patients who often suffer multiple comorbidities.

“The solution lies in redesigning the experience around the patient, thereby providing a more empathetic and coordinated approach to their care.”